Nutriband Stock Up Sharply After Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

Oct 12, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot


Nutriband Inc. (NASDAQ: NTRB) stock is up about 38% on Tuesday after the Company announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 (COVID-19) over an extended period of time.

Vaccine Monitoring

The goal of the Diocheck patch is to monitor the critical gap between when a person receives a COVID-19 vaccine and when a protective level of antibodies is circulating in the body, which current reports suggest could take several weeks. It could also signal when the antibodies stimulated by a vaccine have declined and the person needs a booster.

“This exclusive contract with Diomics to manufacture Diocheck™ allows Nutriband and our contract manufacturing subsidiary, Pocono Pharma, to showcase our capabilities with innovative new patch technologies.”

Gareth Sheridan, CEO of Nutriband

Nutriband Inc. also develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain.